Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CACNA2D1 | P54289 | 16/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20599799 | 0.87 | CACNA2D1 (0.43) | CACNA2D1SLC6A2 | |
| SCHEMBL20917472 | 0.84 | CACNA2D1 (0.41) | ALDH1A1KDM4ELMNAMAPTKMT2A | |
| SCHEMBL22367190 | 0.84 | CACNA2D1 (0.41) | ALDH1A1KDM4ELMNAMAPTKMT2A | |
| SCHEMBL22367327 | 0.83 | ALDH1A1 (0.38) | ALDH1A1KDM4ELMNAMAPTKMT2A | |
| SCHEMBL21946446 | 0.83 | ALDH1A1 (0.38) | ALDH1A1KDM4ELMNAMAPTKMT2A | |
| SCHEMBL21945894 | 0.83 | ALDH1A1 (0.38) | ALDH1A1KDM4ELMNAMAPTKMT2A | |
| SCHEMBL19553331 | 0.81 | SLC7A5 (0.41) | CACNA2D1SLC6A2 | |
| SCHEMBL19553332 | 0.81 | SLC7A5 (0.41) | CACNA2D1SLC6A2 | |
| SCHEMBL21051931 | 0.81 | CACNA2D1 (0.45) | ALDH1A1KDM4ELMNAKMT2ACACNA2D1 | |
| SCHEMBL19553106 | 0.80 | CACNA2D1 (0.42) | CACNA2D1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645528-A1 | COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-05-06 | — | — | EP | disclosed |
| US-20200123115-A1 | COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-04-23 | — | — | US | disclosed |
| WO-2019002173-A1 | COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123115-A1 | COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | TRPV1, CACNG2, CACNA1B | ALDH1A1 1213/4885KDM4E 3932/4885LMNA 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.